Biogen Idec Inc., of Cambridge, Mass., announced two-year phase III data from the ADVANCE trial for Plegridy (peginterferon beta-1a) in relapsing multiple sclerosis (MS) patients. The data, which were presented at the 66th American Academy of Neurology annual meeting in Philadelphia, demonstrated favorable results on relapse rates, magnetic resonance imaging findings and disease progression when dosed every two weeks.